Li AM, Hucks GE, Dinofia AM, et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. ASH Annual Meeting and Exposition 2018, abstract 556.
Allogene anti-CD19 CAR-T-celtherapie voor gerecidiveerde of refractaire B-cel ALL
dec 2022 | Leukemie